What type of study is this?

September 10, 2025Oncology LettersOpen Access

Analysis of camrelizumab in neoadjuvant chemotherapy for esophageal cancer: A retrospective cohort study

View Full Paper

Ask AI

Bookmark

The observation group showed a significant improvement in pCR rates compared to the control group, with 40.0% versus 8.57%.
All patients in the observation group achieved R0 resection, while 91.4% did so in the control group.
Reactive cutaneous capillary endothelial proliferation occurred in 45.7% of the observation group, highlighting safety concerns.
Neoadjuvant camrelizumab with chemotherapy could enhance treatment response in esophageal cancer, pending validation in further trials.

No takes yet. Share an insight, caveat, or question.

Retrospective analysis finds improved outcomes in esophageal cancer patients receiving camrelizumab, suggesting potential therapeutic benefit.

Li et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Retrospective analysis finds improved outcomes in esophageal cancer patients receiving camrelizumab, suggesting potential therapeutic benefit.